Trials / Completed
CompletedNCT00502164
Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer
A Phase I Open-label Dose Escalation Study to Assess the Safety and Tolerability of AZD2171 Following Multiple Oral Doses in Subjects With Advanced Prostate Cancer.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to assess safety and tolerability of AZD2171 after multiple doses in patients with advanced prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD2171 |
Timeline
- Start date
- 2004-03-01
- First posted
- 2007-07-17
- Last updated
- 2011-01-21
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00502164. Inclusion in this directory is not an endorsement.